Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Review today’s 30-year mortgage rate chart to compare trends and identify favorable rates across lenders.
23,821 articlesA new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
A shocking on-stage moment can ripple through a performer's finances. This article breaks down how reportedly used fa...
A broad pullback in software stocks has created compelling opportunities for patient investors. Here are two names wi...
A major investment manager recently disclosed a sizable position in Varonis Systems. This article unpacks what the mo...
AST SpaceMobile sits at a $29 billion valuation despite a modest quarterly revenue. A wave of dilution worries and a ...
The memory market is famous for wild swings. This guide breaks down what Micron does, where demand may come from, and...
Compass, Rocket, and Redfin announce a new syndication to display compass coming soon listings on Redfin's platform, ...
A solid move by a seasoned fund—Alpine Capital Research increases its Arrow Electronics position. Learn what this cou...
As 2026 unfolds, four online real estate schools rise to the top for licensing education, offering flexible formats, ...
A Capitol Hill probe into Epstein-era ties turned volatile this week, with lawmakers veering from policy questions to...
February highlighted a split in space stocks: Iridium rose on stabilizing results, while Redwire and Spacemobile tumb...
Policy shifts around AI chips could change how Nvidia and AMD ship GPUs worldwide. This article breaks down the risks...